TEVA - Teva Pharmaceutical Industries Limited
| Previous Close | 16.91 |
| Open | 16.87 |
| Bid | 16.88 x 1400 |
| Ask | 0.00 x 3000 |
| Day's Range | 16.69 - 17.04 |
| 52 Week Range | 14.59 - 25.96 |
| Volume | 7,174,179 |
| Avg. Volume | 10,859,155 |
| Market Cap | 18.371B |
| Beta (3Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.35 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-11-27 |
| 1y Target Est | 20.50 |
- Zacks•17 hours ago
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
- Zacks•17 hours ago
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.
- Zacks•2 days ago
Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.
- Zacks•6 days ago
BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
- Zacks•7 days ago
Insys Plunges on Auditor's Concern About Insufficient Funds
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
- CNW Group•7 days ago
Why Regulations for Clinical Trials are Resulting in Streamlined Approval Process
PALM BEACH, Florida, March 14, 2019 /CNW/ -- Recent upgrades in international and domestic regulations regarding clinical trials, are both designed to protect patients, but also to upgrade the 'new normal' procedures in clinical trial quality and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting. Internationally, the key regulation is Good Clinical Practice, which is: "Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human subjects. Compliance with GCP assures that the rights, safety, and well-being of trial subjects are protected and that the clinical trial data are credible.
- Morningstar•7 days ago
Is cannabis Big Pharma’s latest drug?
With the medical marijuana market expected to hit US$ 40 billion by 2024, and the potential for cannabis compounds to displace opiates, traditional drugmakers are betting big on weed
- Zacks•9 days ago
Allergan Announces FDA Acceptance of Migraine Candidate NDA
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
- Motley Fool•9 days ago
3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade
These healthcare giants are taking the word "value" to an extreme.
- Zacks•9 days ago
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.
- Reuters•12 days ago
UPDATE 1-OxyContin maker Purdue Pharma loses bid to delay opioid epidemic trial
OxyContin maker Purdue Pharma LP and two other drugmakers on Friday lost a bid to delay a landmark trial set for May in a multibillion-dollar lawsuit by Oklahoma's attorney general accusing them of helping fuel an opioid abuse and overdose epidemic in the state. Cleveland County District Judge Thad Balkman's decision was a win for the state, even as one of the lawyers for the state said Purdue had "threatened" to file for bankruptcy rather than face the first trial to result from around 2,000 lawsuits nationally. Reuters, citing people familiar with the matter, on Monday reported that Stamford, Connecticut-based Purdue, owned by members of the wealthy Sackler family, was exploring filing for Chapter 11 bankruptcy protection.
- Zacks•15 days ago
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
- Motley Fool•15 days ago
Why Teva Pharmaceutical Industries Stock Sank in February
Teva's 2019 outlook sent investors packing last month.
- GlobeNewswire•15 days ago
Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activision Blizzard — Discovering Underlying Factors of Influence
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Market Realist•15 days agoWhat Are Mylan’s Key Growth Drivers in Fiscal 2019?
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY
- Market Realist•16 days ago
What Are Bausch Health’s Key Growth Drivers in 2019?
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Growth drivers In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix
Market Realist•17 days agoBHC and Teva: How Tax Rate, Interest Expenses, and Capex Stack Up
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Comparing the tax rateIn its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) has guided for a non-GAAP adjusted tax rate of 10% for
- Market Realist•17 days ago
BHC and Teva: How Free Cash Flow and Net Debt Stack Up
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Free cash flow projections Bausch Health Companies (BHC) and Teva Pharmaceutical (TEVA) reported free cash flow of $1.27 billion and $1.79 billion, respectively,
- Market Realist•17 days ago
BHC or Teva: Who Is Controlling Expenses Better?
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Expense guidance for fiscal 2018 In its fourth-quarter earnings investor presentation, Bausch Health Companies (BHC) guided for adjusted non-GAAP SG&A
- Business Wire•19 days ago
Teva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United States
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector®1 Patch, 1.3 %, in the U.S. Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions. “The launch of our authorized generic of Flector® Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” said Brendan O’Grady, EVP and Head of North America Commercial.
Market Realist•19 days agoBHC or TEVA: Who Is Expected to Report Faster EPS Growth?
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?(Continued from Prior Part)Earnings guidance for fiscal 2019In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) guided for fiscal 2019 non-GAAP adjusted EBITDA of
- Market Realist•20 days ago
What Analysts Are Recommending for Bausch Health and Teva
Bausch Health or Teva: Which Is a Better Pharmaceutical Bet?Stock price movementsOn February 26, Bausch Health Companies (BHC) closed at $23.16, 0.81% lower than its previous closing price, 60.39% higher than its 52-week low of $14.44, and 18.59%
Motley Fool•21 days agoAntares Pharma Inc (ATRS) Q4 2018 Earnings Conference Call Transcript
ATRS earnings call for the period ending December 31, 2018.
- Zacks•22 days ago
Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down
Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.
Yahoo Finance•23 days agoAmerica's 'inefficient' health care system is driving our fiscal instability: Powell
Health care costs are continuing to grow, and it’s increasingly alarming for policymakers.
